alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
IN THE SUPREME COURT OF PENNSYLVANIA

IN RE: PROMULGATION OF : NO. 492

FINANCIAL REGULATIONS :

PURSUANT TO ACT S 40 AND : J UDICIAL ADMINISTRATION

44 OF 201 7 : DOCKET

ORDER

PER CURIAM :

AND NOW, this 22 nd day of December , 201 7 , it is Ordered

, pursuant to Article V,

Section 10(c) of the Constitution of Pennsylvania and 42 Pa.C.S. § 3502(a), that the

Court Administrator of Pennsylvania is authorized to promulgate the attached Financial

Regulations. The Financial Regulations are effective immedi ately

.

To the extent that notice of proposed rulemaking may be required by Pa.R.J.A.

No. 103 (a) , the immediate promulgation of the regulations is hereby found to be in the

interests of efficient administration. See Pa.R.J.A. No. 103(a)(3).

This Order is t o be processed in accordance with Pa.R.J.A. No. 103(b) a nd is

effective immediately

.
II 

112TH CONGRESS 

2D SESSION S. 2865 

To suspend temporarily the duty on bis (2,3-dibromopropyl ether) of 

Tetrabromobisphenol A. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. PRYOR introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on bis (2,3-dibromopropyl 

ether) of Tetrabromobisphenol A. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. BIS (2,3-DIBROMOPROPYL ETHER) OF 

4 TETRABROMOBISPHENOL A. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 

‘‘ 9902.01.00 Bis (2,3-dibromopropyl ether) 

of Tetrabromobisphenol A 

(CAS No. 21850–44–2) (provided for in subheading 

2909.50.50) ........................... Free No change No change On or before 

12/31/2015 ’’. 


tjames on DSK6SPTVN1PROD with BILLS
2 

•S 2865 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to goods entered, or withdrawn from 

3 warehouse for consumption, on or after the 15th day after 

4 the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2787 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2787

   To extend the temporary suspension of duty on thiophanate methyl.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 7, 2012

   Mr. Casey introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
   To extend the temporary suspension of duty on thiophanate methyl.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. THIOPHANATE METHYL.

    (a) In General.--Heading 9902.03.77 of the Harmonized Tariff 
Schedule of the United States (relating to thiophanate methyl) is 
amended by striking the date in the effective period column and 
inserting ``12/31/2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS 

No. 20-0569V 

UNPUBLISHED 

RENE VILLA, 

 Petitioner, 

v. 

SECRETARY OF HEALTH AND 

HUMAN SERVICES, 

 Respondent. 

Chief Special Master Corcoran 

Filed: August 2, 2021 

Special Processing Unit (SPU); 

Ruling on Entitlement; Concession; 

Table Injury; Influenza (Flu) Vaccine; 

Shoulder Injury Related to Vaccine 

Administration (SIRVA) 

Ronald Craig Homer, Conway, Homer, P.C., Boston, MA, for Petitioner. 

Sarah Black Rifkin, U.S. Department of Justice, Washington, DC, for Respondent. 

RULING ON ENTITLEMENT1

On May 7, 2020, Rene Villa filed a petition for compensation under the National 

Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 (the “Vaccine 

Act”). Petitioner alleges that he received an influenza (“flu”) vaccination on October 13, 

2018, and, thereafter, suffered a left-sided shoulder injury related to vaccine 

administration (“SIRVA”). Petition at 1-2. The case was assigned to the Special 

Processing Unit of the Office of Special Masters. 

On August 2, 2021, Respondent filed his Rule 4(c) report in which he concedes 

that Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at

1. Specifically, Respondent states that Petitioner “had no history of pain, inflammation or

dysfunction in his left shoulder; his pain occurred within 48 hours of receipt of an

1 Because this unpublished ruling contains a reasoned explanation for the action in this case, I am required 

to post it on the United States Court of Federal Claims' website in accordance with the E-Government Act 

of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of Electronic Government 

Services). This means the ruling will be available to anyone with access to the internet. In accordance 

with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information, 

the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that 

the identified material fits within this definition, I will redact such material from public access. 

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease 

of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa 

(2012). 

CORRECTED
2

intramuscular vaccination; his pain and reduced range of motion were limited to the 

shoulder in which the vaccine was administered; and no other condition or abnormality 

was identified to explain his symptoms. Id. at 6. Respondent further agrees that the six 

month sequela requirement has been satisfied and that Petitioner has therefore satisfied 

all legal prerequisites for compensation under the Vaccine Act. Id. 

 In view of Respondent’s position and the evidence of record, I find that 

Petitioner is entitled to compensation. 

IT IS SO ORDERED. 

 s/Brian H. Corcoran 

 Brian H. Corcoran 

 Chief Special Master
[Federal Register Volume 74, Number 72 (Thursday, April 16, 2009)]
[Notices]
[Pages 17667-17668]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-8748]


=======================================================================
-----------------------------------------------------------------------

EQUAL EMPLOYMENT OPPORTUNITY COMMISSION


Commission Meeting

Agency Holding the Meeting: Equal Employment Opportunity Commission.

Date and Time: Wednesday, April 22, 2009, 10 a.m. Eastern Time.

Place: Commission Meeting Room on the First Floor of the EEOC Office 
Building, 131 ``M'' Street, NE., Washington, DC 20507.

Status: The meeting will be open to the public.

Matters to be Considered: 

Open Session: 
    1. Announcement of Notation Votes, and

[[Page 17668]]

    2. Best Practices to Avoid Discrimination Against Caregivers.

    Note: In accordance with the Sunshine Act, the meeting will be 
open to public observation of the Commission's deliberations and 
voting. (In addition to publishing notices on EEOC Commission 
meetings in the Federal Register, the Commission also provides a 
recorded announcement a full week in advance on future Commission 
sessions.)

    Please telephone (202) 663-7100 (voice) and (202) 663-4074 (TTY) at 
any time for information on these meetings. The EEOC provides sign 
language interpretation at Commission meetings for the hearing 
impaired. Requests for other reasonable accommodations may be made by 
using the voice and TTY numbers listed above. Contact Person For More 
Information: Stephen Llewellyn, Executive Officer on (202) 663-4070.

    This Notice Issued April 13, 2009.
Stephen Llewellyn,
Executive Officer, Executive Secretariat.
[FR Doc. E9-8748 Filed 4-15-09; 8:45 am]
BILLING CODE 6570-01-P
##### 



Exhibit 99

BARRISTER GLOBAL SERVICES NETWORKS, INC.

CERTIFICATION
PURSUANT TO 18 U. S. C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Barrister
Global Services Network, Inc. (the Company), does hereby certify, to such
officers knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ending December 31, 2002
(the Form 10-Q) of the Company fully complies with the requirements of
section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the
information contained in the Form 10-Q fairly presents, in all material
respects, the financial condition and results of operations of the Company.

|      |  |                   |  |                                                                                                                                             
|----- |  | ----------------- |  | --------------------------------------------------------------------------------------------------------------------------------------------
|Date: |  | February 14, 2003 |  | By: /s/
          William O. Bray
        William O. Bray
          President and
          Chief Executive Officer                         
|     
|Date: |  | February 14, 2003 |  | By: /s/
          Richard P. Beyer
        Richard P. Beyer
          Senior Vice President, Finance
          (Principal Financial Officer)

21
<PAGE>

EXHIBIT 31.2

                                302 CERTIFICATION

I, James C. Mroczkowski, Executive Vice President and Chief Financial Officer,
certify that:

1) I have reviewed this quarterly report on Form 10-Q of Merchants and
Manufacturers Bancorporation, Inc.;

2) Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3) Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4) The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

      a) designed such disclosure controls and procedures, or caused such
      disclosure controls and procedures to be designed under our supervision,
      to ensure that material information relating to the registrant, including
      its consolidated subsidiaries, is made known to us by others within those
      entities, particularly during the period in which this report is being
      prepared;

      b) evaluated the effectiveness of the registrant's disclosure controls and
      procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of
      the period covered by this report based on such evaluation; and

      c) disclosed in this report any change in the registrant's internal
      control over financial reporting that occurred during the registrant's
      most recent fiscal quarter that has materially affected, or is reasonably
      likely to materially affect, the registrant's internal control over
      financial reporting; and

5) The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent function):

      a) all significant deficiencies and material weaknesses in the design or
      operation of internal control over financial reporting which could
      adversely affect the registrant's ability to record, process, summarize
      and report financial information; and

      b) any fraud, whether or not material, that involves management or other
      employees who have a significant role in the registrant's internal control
      over financial reporting.

Date: May 10, 2004

        /s/ James C. Mroczkowski
        -------------------------------------------------
        James C. Mroczkowski
        Executive Vice President and Chief Financial Officer
II 

112TH CONGRESS 

2D SESSION S. 2767 

To suspend temporarily the duty on dimethyl carbonate polymer with 1,6- 

hexanediol and 1,5-pentanediol. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. CASEY introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on dimethyl carbonate 

polymer with 1,6-hexanediol and 1,5-pentanediol. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. DIMETHYL CARBONATE POLYMER WITH 1,6- 

4 HEXANEDIOL AND 1,5-PENTANEDIOL. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 

‘‘ 9902.01.00 Dimethyl carbonate polymer 

with 1,6-hexanediol and 1,5- 

pentanediol (CAS No. 

126733–01–1) (provided for 

in subheading 3907.99.01) ... Free No change No change On or before 

12/31/2015 ’’. 


rfrederick on DSK6VPTVN1PROD with BILLS
2 

•S 2767 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


rfrederick on DSK6VPTVN1PROD with BILLS
II 

112TH CONGRESS 

2D SESSION S. 2683 

To suspend temporarily the duty on ion exchange resin of benzene, diethenyl, 

polymer, with ethnylbenzene and ethenylethylbenzene, chloromethylated, 

trimethylaminoquaternized. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. CASEY introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on ion exchange resin of 

benzene, diethenyl, polymer, with ethnylbenzene and 

ethenylethylbenzene, chloromethylated, 

trimethylaminoquaternized. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


srobinson on DSK4SPTVN1PROD with BILLS
2 

•S 2683 IS

1 SECTION 1. ION EXCHANGE RESIN OF BENZENE, 

2 DIETHENYL, POLYMER, WITH 

3 ETHNYLBENZENE AND 

4 ETHENYLETHYLBENZENE, 

5 CHLOROMETHYLATED, 

6 TRIMETHYLAMINOQUATERNIZED. 

7 (a) IN GENERAL.—Subchapter II of chapter 99 of 

8 the Harmonized Tariff Schedule of the United States is 

9 amended by inserting in numerical sequence the following 

10 new heading: 

‘‘ 9902.01.00 Ion exchange resin of benzene, diethenyl, polymer, with 

ethnylbenzene and 

ethenylethylbenzene, 

chloromethylated, 

trimethylaminoquaternized 

(CAS No. 69011–19–4) (provided for in subheading 

3914.00.60) ........................... Free No change No change On or before 

12/31/2015 ’’. 

11 (b) EFFECTIVE DATE.—The amendment made by 

12 subsection (a) applies with respect to goods entered, or 

13 withdrawn from warehouse for consumption, on or after 

14 the 15th day after the date of the enactment of this Act. 

Æ 


srobinson on DSK4SPTVN1PROD with BILLS
f8k101811ex10iii_vantone.htm


Exhibit 10.3
<PAGE>

                                                                    EXHIBIT 23.1


                      [LETTERHEAD OF HJ & ASSOCIATES, LLC]






            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors and Shareholders
National Health Partners, Inc.
Horsham, PA

We consent to the incorporation by reference in the registration statements on
Form S-8 of National Health Partners, Inc., Registration Nos. 333-131379 and
333-131589, of our report dated March 20, 2006, with respect to the consolidated
balance sheet of National Health Partners, Inc. and Subsidiary as of December
31, 2005 and the related consolidated statements of operations, stockholders'
equity (deficit) and cash flows for the years ended December 31, 2005 and 2004,
which report appears in the Annual Report on Form 10-KSB of National Health
Partners, Inc. for its fiscal year ended December 31, 2005.


/s/  HJ & Associates, LLC

HJ & Associates, LLC
Salt Lake City, Utah
March 20, 2006
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2872 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2872

 To extend the temporary reduction of duty on certain golf bag bodies.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2012

  Mr. Baucus introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
 To extend the temporary reduction of duty on certain golf bag bodies.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CERTAIN GOLF BAG BODIES.

    (a) In General.--Heading 9902.23.24 of the Harmonized Tariff 
Schedule of the United States (relating to certain golf bag bodies) is 
amended by striking the date in the effective period column and 
inserting ``12/31/2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
EXHIBIT 32.1
                            CERTIFICATION PURSUANT TO
                                 18 U.S.C. 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report of NAVIDEC  FINANCIAL  SERVICES,  INC. (the
"Company") on Form 10-KSB for the period ended  December 31, 2007, as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report"),  I,
John R. McKowen, President and Chief Accounting Officer of the Company, certify,
pursuant  to 18  U.S.C.  1350,  as  adopted  pursuant  to  Section  906  of  the
Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and

The  information  contained  in the  Report  fairly  presents,  in all  material
respects, the financial condition and results of operations of the Company.




Date: April 14, 2008



By:       /s/ John R. McKowen
         -----------------------------
         John R. McKowen
         Chief Accounting Officer and President
EXHIBIT 99.1 – CERTIFICATION OF CEO

 

CERTIFICATIONS

 

I, Tom L Kirchner, certify that:

 - I have reviewed this quarterly report on Form 10-QSB of Electronic Systems Technology    Inc.;    
- Based on my knowledge, this quarterly report does not contain any untrue statement of a    material fact or omit to state a material fact necessary to make the statements made, in    light of the circumstances under which such statements were made, not misleading with    respect to the period covered by this quarterly report;    
- Based on my knowledge, the financial statements, and other financial information    included in this quarterly report, fairly present in all material respects the financial    condition, results of operations and cash flows of the Registrant as of, and for, the    periods presented in this quarterly report;  
- The Registrant’s other certifying officers and I are responsible for establishing    and maintaining disclosure controls and procedures (as defined in Exchange Act Rules    13a-14 and 15d-14) for the Registrant and have:  
- designed such disclosure controls and procedures to ensure that material information    relating to the Registrant, including its consolidated subsidiaries, is made known to us    by others within those entities, particularly during the period in which this quarterly    report is being prepared;    
- evaluated the effectiveness of the Registrant’s disclosure controls and procedures    as of a date within 90 days prior to the filing date of this quarterly report (the    "Evaluation Date"); and     
- presented in this quarterly report our conclusions about the effectiveness of the    disclosure controls and procedures based on our evaluation as of the Evaluation Date;
- The Registrant’s other certifying officers and I have disclosed, based on our most    recent evaluation, to the Registrant’s auditor’s and the audit committee of    Registrant’s board of directors (or persons performing the equivalent functions):
- all significant deficiencies in the design or operation of internal controls which could    adversely affect the Registrant’s ability to record, process, summarize and report    financial data and have identified for the Registrant’s auditors any material    weaknesses in internal controls; and    
- any fraud, whether or not material, that involves management or other    employees who have a significant role in the Registrant’s internal controls; and- The Registrant’s other certifying officers and I have indicated in this quarterly    report whether or not there were significant changes in internal controls or in other    factors that could significantly affect internal control subsequent to the date of our    most recent evaluation, including any corrective actions with regard to  significant    deficiencies and material weaknesses.
Date: November 7, 2002/s/ TOM L KIRCHNER Tom L. Kirchner President and Chief Executive Officer
##### 



Exhibit 99.2 ANNUAL STATEMENT OF COMPLIANCEPrincipal Life Income Fundings Trust 2004-57 (the Trust) I, Nancy H. Forte, a duly elected and acting officer of Citibank, N.A. (Indenture Trustee),
do hereby certify on behalf of the Indenture Trustee, that: 1. I have reviewed and examined the performance by the Indenture Trustee of the application of
trust money collected by the Indenture Trustee pursuant to Section 5.02 and, if applicable, Section
6.06 of the Indenture pursuant to which the Trusts notes were issued during the fiscal year ending
December 31, 2004 (the Relevant Year); and 2. Based upon my review and examination described in 1 above, and except as provided in the
Report of Independent Registered Public Accounting Firm on Compliance, dated March 15, 2005,
prepared by the Ernst & Young LLP substantially in accordance with Section 4.05 of the Expense and
Indemnity Agreement, to the best of my knowledge, the application of trust money collected by the
Indenture Trustee pursuant to Section 5.02 and, if applicable, Section 6.06 of the Indenture was
performed in accordance with the terms of the Indenture throughout the Relevant Year. CITIBANK, N.A., as Indenture TrusteeBy:
    /s/ Nancy H. ForteName:
    Nancy H. ForteTitle:
    Assistant Vice President Date: March 29, 2005